A B S T R A C T The liver has been shown to remove parathyroid hormone (PTH) from its arterial circulation by a mechanism that is selective for the intact form of the peptide . The These results suggest that the liver is a target organ of PTH, and that PTH might potentially alter carbohydrate metabolism during hypersecretion. They also suggest that hepatic uptake of PTH may be related in part to production of a specific biologic effect rather than just simple peptide degradation. INTRODUCTION We have demonstrated (1) that the liver is a major site of uptake for bovine parathyroid hormone (b-PTH)l in the
INTRODUCTION
We have demonstrated (1) that the liver is a major site of uptake for bovine parathyroid hormone (b-PTH)l in the Receivedfor publication 23 September 1978 and in revised form 11 May 1979. 'Abbreviations used in this paper: A -V, arterial minus awake dog. The hepatic uptake mechanism for b-PTH was found to be specific for the intact form of the hormone (PTH 1-84) and no uptake of COOH-or NH2-terminal fragments could be demonstrated. In addition, no hepatic uptake was demonstrable for biologically active synthetic NH2-terminal tetratricontapeptide (syn b-PTH 1-34). Addition of COOH-terminal fragments to hepatic venous plasma was observed after b-PTH 1-84 injections, indicating degradation of b-PTH 1-84 by the liver after its uptake. The observation of selective hepatic uptake of b-PTH 1-84 and lack of uptake of PTH fragments including syn b-PTH 1-34 raised the question of whether this difference also applied to the expression of biological effects of PTH on the liver. The liver has not been demonstrated to be a major target organ for PTH in vivo. However, PTH has been shown to markedly stimulate renal gluconeogenesis in vitro (2, 3) , and to have slight to moderate effects in stimulating hepatic adenylate cyclase, glycogenolysis, and gluconeogenesis in rat liver homogenates and hepatocytes (4, 5) . In addition, PTH inhibition of glycogen synthesis has been demonstrated in the isolated perfused rat liver (6) .
Thus, these studies were designed to investigate possible biological effects of PTH on the liver in vivo and determine if the difference in uptake between b-PTH 1-84 and syn b-PTH 1-34 extended to the expression of biologic activity of the hormone.
METHODS
Preparation of dogs. Mongrel dogs weighing 18-26 kg were fed a standard high protein Purina dog chow (Ralston Purina Co., St. Louis, Mo.) and had free access to water. Before study during laparotomy, catheters were placed in the left common hepatic vein, as described (1) by the method of Shoevenous concentration; A -PV, arterial minus portal vein glucose concentration; b-PTH, bovine PTH; HV -A, hepatic venous minus arterial glucose concentration; HV -PV hepatic vein minus portal vein glucose concentration; PTH, parathyroid hormone; syn b-PTH 1-34, synthetic NH2-terminal tetracontapeptide. maker et al. (7) , and the portal vein. Catheter patency was maintained by intermittent filling with heparin. After surgery, the dogs were followed closely for resumption of normal food intake and return of bowel function. The shortest time interval after surgery to study was 48 h. Dogs that were not eating full rations or having normal formed stools were not studied.
Study protocol. Dogs were studied awake and resting in a sling after a 12-h fast. The femoral artery was catheterized by the Seldinger technique (8) and a polyethylene catheter was advanced into the aorta to the approximate level of the celiac axis. A hind leg vein catheter was placed for infusion of solutions, and injections of PTH.
Hepatic plasma flow was measured by reported methods (1) using constant infusion of indocyanine green (ICG; Hynson, Westcott & Dunning, Inc., Baltimore, Md.). The hepatic arteriovenous difference for ICG also served as a marker for adequacy of hepatic venous sampling to exclude contamination of samples with inferior vena cava blood (9) .
Control aortic, hepatic, and portal vein plasma samples were obtained at 60, 30, and 10 min before injection of PTH preparations. After injections of 2.5 ug/kg b-PTH 1-84, 2.5
Ag/kg syn b-PTH 1-34 or an equal volume of vehicle used in reconstituting PTH, blood samples were obtained from the three catheters simultaneously every 5-20 min for up to 100 min after injection. All blood samples were collected in heparinized tubes and centrifuged immediately. The plasma was separated into aliquots, and stored at -40°C. In those tubes for glucagon and insulin determinations, Trasylol (100 ,ll; FBA Pharmaceuticals, Inc., New York) was present as a preservative in each test tube. Glucose and ICG were determined immediately after centrifugation. Studies w;ith isotope infusions. These studies were conducted as described above except that an infusion of [U-_4C]-alanine (New England Nuclear, Boston, Mass.) 0.15 ,tCi/kg per h was begun after a priming dose of 0.1 ,uCi/kg and continued throughout the study. 120 min of isotope infusion was allowed for equilibration before control blood samples were obtained from hepatic vein, portal vein, and aortic catheters at 120, 140, 160, and 180 min of infusion. After control bloods were obtained, a b-PTH 1-84 infusion (12-15 ng/kg) was begun. The PTH infusion was designed to maintain immunoassayable PTH levels of 1 ng/ml. An additional period of 60 min was allowed for reequilibration of isotope before experimental bloods were drawn from all catheters at 240, 260, 280, and 300 min of [U-14C]alanine infusion. Blood samples for isotopic counting were transferred immediately to tubes containing an equal volume of perchloric acid (3 mM).
Sources of PTH. b-PTH 1-84 was obtained from Inolex Biomedical Div., Glenwood, Ill. (1,100-1,500 U/mg sp act in the Munson bioassay). Syn b-PTH 1-34 was obtained from Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif. (3,700 U/mg sp act in a renal adenylate cyclase system). Both PTH preparations were reconstituted in 0.2% acetic acid, pH 3.5, and added to dog plasma for injection. Biologic activity of all PTH preparations was established by their ability to decrease the tubular reabsorption of phosphorus in the dogs studied and to stimulate 3'5'-cyclic AMP production in isolated canine renal tubules. The methods employed in the incubation of PTH preparations with canine renal tubules have been reported (10) . Levels of 3'5'-cyclic AMP were determined by radioimmunoassay according to the method of Steiner et al. as reported (11) . 125I-3'5'-cyclic AMP used as a tracer in the radioimmunoassay was purchased from New England Nuclear.
Chemical determinations. Glucose was determined by the glucose oxidase method with a Beckman glucose analyzer (Beckman Instruments, Inc., Fullerton, Calif.). In samples from the isotopic infusion studies, glucose was determined in a microfluorometric assay as described below. Radioimmunoassays for plasma glucagon and insulin were performed in the Washington University Diabetes Center by reported methods (12, 13) . Creatinine and phosphorus were determined by reported methods (1) .
Isotopic couniting. Samples for the determination of ['4C]alanine were prepared by the method of Garber et al. (14) . Blood samples were added to an equal volume of 3 mM perchloric acid and centrifuged. The supernate was neutralized with a potassium hydroxide-imidazole mixture and then added to a 1 x 4-cm column of Dowex AG-X8 (Dow Corning Co. Midland, Mich.) to remove lactate. The column eluate was placed on a second column of Dowex AG-50-X8 and the initial eluate No. 1 was collected. The columns were then treated with 3 N ammonium hydroxide and a second eluate collected. Eluate No. 1 was lyophilized to dryness, reconstituted, and measured for total glucose content. Eluate No. 2 was lyophilized, reconstituted with 0.02 N sodium citrate (pH 3.5) and placed on a 1 x 20-cm column of HPB80 and eluted with 0.2 N sodium citrate. The alanine eluate was lyophilized, reconstituted and counted for 14C radioactivity and total alanine vas assayed with a fluorometric assay (15) . Glucose was determined using a microfluorometric assay (16) in eluate No. 1 from the Dowex AG-50-X8 column. Alanine recoveries ranged from 82 to 98%. Radioisotope counting was performed in a refrigerated liquid scintillation spectrophotometer (Searle Analytic, Inc., Des Plaines, Ill.).
Calculations. Hepatic plasma flowr (HPF) was calculated by dividing the metabolic clearance rate of ICG (infusion rate in micrograms per minute divided by arterial ICG micrograms per milliliter) by the hepatic arterial minus venous concentration (A -V) difference for ICG. Glucose addition to the hepatic venous blood wvas calculated as the product of the hepatic venous minus arterial glucose concentration (HV -A) difference and the HPF. Because there was a small arterialportal A -V difference at all times, the calculated hepatic glucose production rates as performed represent an underestimate. Because electromagnetic flow probe methodology for direct determination of hepatic arterial and portal venous blood flow was not available, hepatic alanine uptake was calculated as the product of an estimate of alanine delivery to the liver and the hepatic extraction of alanine. Alanine delivery was estimated as the product of 2(portal alanine) plus arterial alanine/3 and the HPF, because the delivery from portal venous blood accounts for -two-thirds of delivery in basal conditions (17) . After PTH injections, alanine delivery was estimated as the product of portal alanine plus arterial alanine/2 and the HPF, because PTH increases the percentage of hepatic blood flow from the systemic circulation to-50% (17) . Hepatic alanine extraction was calculated by the formula, estimated alanine delivery concentration minus hepatic vein alanine/estimated alanine delivery concentration. The estimated alanine delivery concentration was calculated as above in base-line periods and after PTH injections. These calculations again take into account the sources of hepatic blood flow and the effects of PTH on portal venous and hepatic arterial blood flow (17) . The use of the calculations that took into account redistribution of hepatic blood supply after PTH did not significantly affect the results of estimated alanine uptake compared to calculations that employed onlv the mean of the portal and arterial alanine concentrations, without redistribution of blood flow, as the alanine delivered.
RESULTS
The hepatic handliiig of ICG by the dogs used in these studies is shown in Table I along with the mean Because the portal vein venous glucose concentration was 0-4 mg/dl less than arterial glucose concentration at any point, a minimal estimate of glucose addition Alanine uptake studies. To investigate the relationship between the hepatic gluconeogenic substrate, alanine, and the changes in hepatic glucose production shown above, the effect of PTH on estimated hepatic alanine uptake was examined. Hepatic alanine uptake calculated as described above in Methods was significantly increased by b-PTH 1-84 injections (Fig. 2) . This increase in hepatic uptake was present at all intervals tested after injections (5-60 min). Mean+SEM arterial alanine levels were 234+5 ,uM during control periods and 246+8 ,uM in the plasma samples obtained after bolus b-PTH 1-84 injections. Portal alanine levels were 267+8 ,.uM in control periods and 278±5 ,uM after PTH administration. Hepatic vein alanine concentrations fell from 222±9 ,uM control to 195±8 ,uM after PTH. Thus, several factors may have contributed to the increase in hepatic alanine uptake observed after b-PTH 1-84 administration. In depth evaluation of each ofthese factors (increased peripheral and/or splanchnic alanine delivery and increased hepatic alanine extraction) was beyond the scope of the present studies. As shown in Fig. 2 , injections of syn b-PTH 1-34 were not followed by an increase in the hepatic uptake ofalanine.
[14C]Alanine infusion studies. To further characterize the effect ofb-PTH 1-84 on hepatic glucose release at inore physiologic levels ofthe hormone, studies were undertaken in normal dogs injected with PTH so as to maintain serum levels in the hyperparathyroid range (1 ng/ml). These studies were also performed during infusion of alanine uniformly labeled with F4C. Table II (1) . The studies during syn b-PTH 1-34 administration again revealed no effect on hepatic alanine uptake. Changes in plasma glucagon and insulin. Because changes in glucose concentrations would be expected to alter glucagon and insulin release, the plasma levels of these hormones were followed during the course of these studies. As shown on Fig. 4A , there was a tendency for mean plasma glucagon to decrease after the injection of b-PTH 1-84. As shown in Fig. 4B , there was an increase in arterial insulin levels after b-PTH 1-84 administration. Mean plasma insulin levels were significantly increased at 10 and 60 min after PTH as compared to base-line periods in the groups of dogs receiving b-PTH 1-84.
DISCUSSION
We have reported (1) a specific uptake and degradation of b-PTH 1-84 by the canine liver in vivo. We also found no demonstrable hepatic uptake of syn b-PTH 1-34 or COOH-terminal PTH fragments. The present studies demonstrate biologic effects of b-PTH 1-84 on the canine liver. b-PTH 1-84 administration increased glucose release from the liver and stimulated gluconeogenesis from alanine. On the other hand, administration of syn b-PTH 1-34 had no demonstrable effect on glucose release. Thus, the uptake of b-PTH 1-84 by the liver was correlated with a specific biologic effect, and absence of uptake of syn b-PTH 1-34 with absence of such an effect. These studies suggest that hepatic PTH uptake is related to specific biologic effects of the hormone, and that the liver is more than just a site of degradative uptake of PTH.
PTH hormone has been shown to increase adenylate cyclase activity and 3'5'-cyclic AMP concentrations in rat liver cells and homogenates in vitro (4, 5) . In addition, PTH stimulated gluconeogenesis, glycogenolysis, and urea production in isolated rat liver cells. Thus, in vitro studies suggested that the liver might represent a target organ of PTH biologic activity. The doses of PTH employed to demonstrate the above-mentioned effects (1-0.1 ,M) were clearly pharmacologic but this was also the case in studies related to the effects of 1-84  single injections  1  5  25  5  42  69  48  101  69  64  48  45  2  27  27  23  46  53  68  42  49  57  110  3  45  45  0  125  80  100  50  25  50  5  5  4  0  6  0  11  44  50  44  66  50  5 (20, 21) and in chronic renal failure (22) . The role of PTH in the altered carbohydrate metabolism observed in these states has not been examined.
The absence of an effect of syn b-PTH 1-34 on hepatic glucose production in the present studies is in contrast to previous studies performed in isolated rat liver hepatocytes and homogenates (5) . In these studies FIGURE 4 Mean±SEM arterial glucagon and insulin levels after b-PTH 1-84 injections. There was a tendency for arterial glucagon to fall. The rises in arterial insulin were significantly different at 10 and 60 min after injection (*, P < 0.05).
syn b-PTH 1-34 stimulated adenylate cyclase activity and both glycogenolysis and gluconeogenesis to a degree equal to the effects seen with b-PTH 1-84. Obvious differences between these previous studies and those reported here may explain the discrepant results obtained. These differences include a different species of animal studied and the difficulty of comiiparinlg in vitro results to in vivo studies. However, no definite explanation for the observed differences in response to syn b-PTH 1-34 was apparent during the present studies.
The mechanisms responsible for the increase in hepatic glucose production after b-PTH 1-84 injections appeared to involve both increased glycogenolysis and gluconeogenesis judging from the rapidity of the increase in hepatic venous glucose concentration and the duration ofthe PTH effect for 80 min after injection. PTH has been shown in vitro to affect both of these processes responsible for increasing hepatic glucose production (5, 6). The results of the present study demonstrate increased estimated hepatic uptake of alanine extending from 10-60 min after bolus injections of b-PTH 1-84. These results suggest that alanine was one of the substrates involved in the increased gluconeogenesis observed after b-PTH administration. The mechanismn of increased alanine uptake involved both increased delivery from arterial and portal venous sources in individual dogs and an increase in hepatic alanine extraction. The studies during ["4C]alanine infusion suggest that increased hepatic extraction of alanine was an important factor in the increased hepatic alanine uptake. These studies do not necessarily confirm that PTH stimulates alanine release from striated muscle as suggested by Garber (23) in vitro, because a consistent rise in arterial alanine levels was not observed in all dogs.
The observed changes in arterial glucagon and insulin levels after b-PTH 1-84 injections are those to be expected after a glucose load. Thus, these results both confirm the presence of increased glucose production after b-PTH 1-84 and suggest that the changes in the plasma levels of insulin and glucagon were secondary and did not contribute to the observed increased hepatic glucose production.
In conclusion, these studies demonstrate an effect of intact PTH on hepatic glucose production in vivo. They extend our previous report, which demonstrated specificity of canine hepatic uptake for the intact form of PTH. The demonstration that syn b-PTH 1-34 failed to stimulate hepatic glucose production and was not taken up by the liver is consistent with a close correlation between uptake and the effects of PTH on glucose release. It is suggested that future studies of hepatic PTH metabolism consider the biologic actions of PTH on the liver and not focus solely on this organ as a peptide degradation site.
